- Home
- POLE vs IVA Comparison
POLE vs IVA Comparison
Compare POLE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLE
- IVA
- Stock Information
- Founded
- POLE 2024
- IVA 2011
- Country
- POLE United States
- IVA France
- Employees
- POLE N/A
- IVA N/A
- Industry
- POLE
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- POLE
- IVA Health Care
- Exchange
- POLE NYSE
- IVA Nasdaq
- Market Cap
- POLE 299.8M
- IVA 359.6M
- IPO Year
- POLE 2024
- IVA 2020
- Fundamental
- Price
- POLE $10.25
- IVA $3.58
- Analyst Decision
- POLE
- IVA Strong Buy
- Analyst Count
- POLE 0
- IVA 4
- Target Price
- POLE N/A
- IVA $10.50
- AVG Volume (30 Days)
- POLE 88.3K
- IVA 18.0K
- Earning Date
- POLE 01-01-0001
- IVA 03-26-2025
- Dividend Yield
- POLE N/A
- IVA N/A
- EPS Growth
- POLE N/A
- IVA N/A
- EPS
- POLE N/A
- IVA N/A
- Revenue
- POLE N/A
- IVA $14,591,573.00
- Revenue This Year
- POLE N/A
- IVA $15.38
- Revenue Next Year
- POLE N/A
- IVA $24.22
- P/E Ratio
- POLE $57.91
- IVA N/A
- Revenue Growth
- POLE N/A
- IVA N/A
- 52 Week Low
- POLE $9.94
- IVA $1.53
- 52 Week High
- POLE $11.16
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- POLE N/A
- IVA 54.47
- Support Level
- POLE N/A
- IVA $3.48
- Resistance Level
- POLE N/A
- IVA $3.77
- Average True Range (ATR)
- POLE 0.00
- IVA 0.22
- MACD
- POLE 0.00
- IVA -0.03
- Stochastic Oscillator
- POLE 0.00
- IVA 48.68
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.